Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
vlag UCB 31/05 128,650 EUR
+1,70% 		+1,70%

Nieuws over “Farmaceutica”

31/05 · Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement · Persbericht

31/05 · Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement · Persbericht

31/05 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics · Persbericht

31/05 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen · Persbericht

31/05 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint · Persbericht

31/05 · Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML · Persbericht

31/05 · Viatris to Participate in the Jeffries Global Healthcare Conference · Persbericht

31/05 · Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan · Persbericht

31/05 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

31/05 · Europees aandelennieuws · Bolero.be

KKR mag vaste lijnen van Telecom Italia overnemen De Amerikaanse investeringsmaatschappij KKR heeft  onvoorwaardelijke goedkeuring gekregen van de Europese mededingingsautoriteiten voor de overname van de vaste lijn in het...

31/05 · Beursnieuws België en Nederland · Bolero.be

DSM Firmenich optimaliseert de financieringsstructuur Het Zwitsers-Nederlands bedrijf en producent van voedingsstoffen, smaken en geuren meldt een optimalisering van de financieringsstructuur. Het gaat om een kruislingse...

31/05 · AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis · Persbericht

31/05 · Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD · Persbericht

31/05 · Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation · Persbericht

31/05 · Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 · Persbericht

31/05 · Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria · Persbericht

31/05 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

30/05 · CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

30/05 · Ipsen announces the launch of an employee shareholding plan · Persbericht

30/05 · Press Release: Sanofi completes acquisition of Inhibrx, Inc. · Persbericht

30/05 · Genprex to Present at the 2024 BIO International Convention · Persbericht

Mijn selecties